The Impact of Karyotype on Remission Rates in Adult Patients with de novo Acute Myeloid Leukemia Receiving High-Dose Cytarabine-Based Induction Chemotherapy

References

• Yunis J J, Lobell M, Amesen M A, et al. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 1988; 68: 189–194
   PubMed Web of Science ®Google Scholar
• Schiffer C A, Lee E J, Tomiyasu T, Wiemik P H, Testa J R. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73: 263–270
   PubMed Web of Science ®Google Scholar
• Zittoun R, Jehn U, Fière D, et al. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood 1989; 73: 896–906
   PubMed Web of Science ®Google Scholar
• Fenaux P, Preudhomme C, Laï J L, Morel P, Beuscart R, Bau‐ters F. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. Br J Haematol 1989; 73: 61–67
   PubMed Web of Science ®Google Scholar
• Ghaddar H M, Plunkett W, Kantarjian H M, et al. Long‐term results following treatment of newly‐diagnosed acute myelogenous leukemia with continuous‐infusion high‐dose cytosine arabinoside. Leukemia 1994; 8: 1269–1274
   PubMed Web of Science ®Google Scholar
• Bloomfield C D, Lawrence D, Arthur D C, Berg D T, Schiffer C A, Mayer R J. Curative impact of intensification with high‐dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 1994; 84(Suppl 1)111a
   PubMed Web of Science ®Google Scholar
• Ferrant A, Doyen C, Delannoy A, et al. Karyotype in acute myeloblastic leukemia: prognostic significance in a prospective study assessing bone marrow transplantation in first remission. Bone Marrow Transplant 1995; 15: 685–690
   PubMed Web of Science ®Google Scholar
• Gale R P, Horowitz M M, Weiner R S, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995; 16: 203–208
   PubMed Web of Science ®Google Scholar
• Burnett A K, Goldstone A H, Stevens R, Hann I, Rees J K, Wheatley K. Biological characteristics of disease determine the outcome of allogeneic and autologous BMT in CRl. Blood 1995; 86(Suppl 1)616a
   Google Scholar
• Wheatley K, Burnett A, Goldstone A, et al. A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom Medical Research Council (MRC) AML10 trial. Blood 1995; 86(Suppl 1)598a
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison C, et al. Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial. Blood 1996; 88(Suppl 1)634a
   Google Scholar
• Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997; 90: 2931–2938
   PubMed Web of Science ®Google Scholar
• Stein A, O'Donnell M R, Slovak M L, et al. Cytogenetics predict complete remission rate for adult patients with de novo acute myelogenous leukemia treated with high‐dose cytarabine. Blood 1997; 90(Suppl 1)64a
   PubMed Web of Science ®Google Scholar
• Arlin Z, Case D C, Jr, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990; 4: 177–183
   PubMed Web of Science ®Google Scholar
• Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666–1674
   PubMed Web of Science ®Google Scholar
• Vogler W R, Winton E F, Gordon D S, Raney M R, Go B, Meyer L. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial. Blood 1984; 63: 1039–1045
   PubMed Web of Science ®Google Scholar
• Wiemik P H, Banks P LC, Case D C, Jr., et al. Cytara‐bine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313–319
   PubMed Web of Science ®Google Scholar
• Bishop J F, Matthews J P, Young G A, et al. A randomized study of high‐dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710–1717
   PubMed Web of Science ®Google Scholar
• Weick J K, Kopecky K J, Appelbaum F R, et al. A randomized investigation of high‐dose versus standard‐dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841–2851
   PubMed Web of Science ®Google Scholar
• Hann I M, Stevens R F, Goldstone A H, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Blood 1997; 89: 2311–2318
   PubMed Web of Science ®Google Scholar
• Parikh P, Powles R, Treleaven J, et al. High‐dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study. Br J Cancer 1990; 62: 830–833
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Singhal S, et al. Idarubicin, high‐dose cytarabine and etoposide for induction of remission in acute leukemia. Semin Hematol 1996; 33(Suppl 3)18–23
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French‐American‐British Cooperative Group. Ann Intern Med 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French‐American‐British Cooperative Group. Ann Intern Med 1985; 103: 460–462
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO). Br J Haematol 1991; 78: 325–329
   PubMed Web of Science ®Google Scholar
• Catovsky D, Matutes E, Buccheri V, et al. A classification of acute leukaemia for the 1990s. Ann Hematol 1991; 62: 16–21
   PubMed Web of Science ®Google Scholar
• Hioms L R, Swansbury G J, Mehta J, et al. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 1997; 96: 314–321
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Horton C, et al. Bone marrow transplantation for primary refractory acute leukaemia. Bone Marrow Transplant 1994; 14: 415–418
   PubMed Web of Science ®Google Scholar
• Estey E, Thall P F, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulo‐cyte‐macrophage colony‐stimulating factor (GM‐CSF) before and during continuous‐infusion high‐dose ara‐C + daunombicin: comparison to patients treated without GM‐CSF. Blood 1992; 79: 2246–2255
   PubMed Web of Science ®Google Scholar
• Herzig R H, Lazarus H M, Wolff S N, Phillips G L, Herzig G P. High‐dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 1985; 3: 992–997
   PubMed Web of Science ®Google Scholar
• Kulkami S, Powles R, Eisen T, et al. High‐dose cytarabine and VP‐16 with or without idarubicin for relapsed acute leukemia. Blood 1986; 88(Suppl 1)174b
   Google Scholar
• Head D, Kopecky K J, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995; 86: 1717–1728
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Singhal S, et al. Autologous bone marrow transplantation for acute rnyeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 1995; 16: 499–506
   PubMed Web of Science ®Google Scholar
• Powles R, Treleaven J, Singhal S, et al. Total therapy of acute myeloid leukemia: 7‐ear follow‐up. Blood 1997; 90(Suppl 1)227a
   Google Scholar
• Mitus A J, Miller K B, Schenkein D P, et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995; 13: 560–569
   PubMed Web of Science ®Google Scholar